Seed and early stage investments in exceptional technology and life sciences companies.
AstraZeneca to collaborate with Biognosys on large proteome quantification (24/11/2014)
Biognosys (RAC I), the leading proteomics company offering services and products for highly multiplexed protein quantification, just announced a collaboration with AstraZeneca, who will use Biognosys’ recently launched Proteome – SEQ™ service. This is another addition to a growing list of leading pharmaceutical companies using the next-generation proteomics technology of Biognosys. Proteome-SEQ™ is a comprehensive [...] More.
Portfolio Update: InSphero, MedMira and the Rebranding of Ebuzzing (09/10/2014)
We have witnessed an exciting start into the last quarter of the year with a lot of activity across our portfolio companies. Here are some highlights to keep you up-to-date: After taking top spot in the Swiss TOP 100 Startup Awards last month, InSphero (RAC I) has now won also the pan-European ACES award for [...] More.
Redalpine invests in Knip – Switzerland’s first fully digital insurance broker (06/10/2014)
Redalpine welcomes another truly disruptive company to its Capital II portfolio. Knip, Switzerland’s first fully digital insurance broker, offers an unrivalled user experience: Insurance policies overview and management combined with smart analysis to optimise your insurance portfolio and easy claims notifications – all conveniently packaged into a smartphone app. Insurance app Knip secures Series A [...] More.